Nerve growth factor

An update on the science and therapy

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Objective: Nerve growth factor (NGF) is a key regulator of nociceptive pain and thus appears to be an interesting target molecule for an innovative class of analgesic medication. We set out to review the principles of neurogenic inflammation and results of anti-NGF regimens in animal studies as well as clinical trials with patients with back pain and osteoarthritis (OA). Design: We searched using Google Scholar Search and Pubmed as well as through conference reports for articles and abstracts related to NGF and clinical trials using anti-NGF regimens. We report on efficacy findings and adverse events (AEs) related to these agents in this review. Results: We identified five full articles and eight abstract reports relating to anti-NGF agents studied for use in back pain and in OA. Conclusions: Anti-NGF agents either alone or in combination with non-steroidal anti-inflammatory agents (NSAIDs) were more efficacious for the treatment of pain in a number of trials of knee and hip pain compared to NSAIDs alone. However, adverse effects that included rapidly progressive OA and joint replacement were more common in patients treated with anti-NGF and NSAIDs than either treatment alone. Anti-NGF treatment related neurologic symptoms including paresthesias, and potentially other types of adverse effects were usually transient but warrant additional investigation.

Original languageEnglish (US)
Pages (from-to)1223-1228
Number of pages6
JournalOsteoarthritis and Cartilage
Volume21
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Nerve Growth Factor
Non-Steroidal Anti-Inflammatory Agents
Osteoarthritis
Therapeutics
Back Pain
Replacement Arthroplasties
Clinical Trials
Neurogenic Inflammation
Nociceptive Pain
Pain
Intercellular Signaling Peptides and Proteins
Paresthesia
Neurologic Manifestations
PubMed
Analgesics
Hip
Knee
Animals
Molecules

Keywords

  • Nerve growth factor
  • Neurogenic inflammation
  • Osteoarthitis
  • Receptor antagonists

ASJC Scopus subject areas

  • Biomedical Engineering
  • Orthopedics and Sports Medicine
  • Rheumatology

Cite this

Nerve growth factor : An update on the science and therapy. / Seidel, M. F.; Wise, Barton L; Lane, Nancy E.

In: Osteoarthritis and Cartilage, Vol. 21, No. 9, 09.2013, p. 1223-1228.

Research output: Contribution to journalArticle

@article{de05166e18714ecba05c9c2b1591c28d,
title = "Nerve growth factor: An update on the science and therapy",
abstract = "Objective: Nerve growth factor (NGF) is a key regulator of nociceptive pain and thus appears to be an interesting target molecule for an innovative class of analgesic medication. We set out to review the principles of neurogenic inflammation and results of anti-NGF regimens in animal studies as well as clinical trials with patients with back pain and osteoarthritis (OA). Design: We searched using Google Scholar Search and Pubmed as well as through conference reports for articles and abstracts related to NGF and clinical trials using anti-NGF regimens. We report on efficacy findings and adverse events (AEs) related to these agents in this review. Results: We identified five full articles and eight abstract reports relating to anti-NGF agents studied for use in back pain and in OA. Conclusions: Anti-NGF agents either alone or in combination with non-steroidal anti-inflammatory agents (NSAIDs) were more efficacious for the treatment of pain in a number of trials of knee and hip pain compared to NSAIDs alone. However, adverse effects that included rapidly progressive OA and joint replacement were more common in patients treated with anti-NGF and NSAIDs than either treatment alone. Anti-NGF treatment related neurologic symptoms including paresthesias, and potentially other types of adverse effects were usually transient but warrant additional investigation.",
keywords = "Nerve growth factor, Neurogenic inflammation, Osteoarthitis, Receptor antagonists",
author = "Seidel, {M. F.} and Wise, {Barton L} and Lane, {Nancy E}",
year = "2013",
month = "9",
doi = "10.1016/j.joca.2013.06.004",
language = "English (US)",
volume = "21",
pages = "1223--1228",
journal = "Osteoarthritis and Cartilage",
issn = "1063-4584",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Nerve growth factor

T2 - An update on the science and therapy

AU - Seidel, M. F.

AU - Wise, Barton L

AU - Lane, Nancy E

PY - 2013/9

Y1 - 2013/9

N2 - Objective: Nerve growth factor (NGF) is a key regulator of nociceptive pain and thus appears to be an interesting target molecule for an innovative class of analgesic medication. We set out to review the principles of neurogenic inflammation and results of anti-NGF regimens in animal studies as well as clinical trials with patients with back pain and osteoarthritis (OA). Design: We searched using Google Scholar Search and Pubmed as well as through conference reports for articles and abstracts related to NGF and clinical trials using anti-NGF regimens. We report on efficacy findings and adverse events (AEs) related to these agents in this review. Results: We identified five full articles and eight abstract reports relating to anti-NGF agents studied for use in back pain and in OA. Conclusions: Anti-NGF agents either alone or in combination with non-steroidal anti-inflammatory agents (NSAIDs) were more efficacious for the treatment of pain in a number of trials of knee and hip pain compared to NSAIDs alone. However, adverse effects that included rapidly progressive OA and joint replacement were more common in patients treated with anti-NGF and NSAIDs than either treatment alone. Anti-NGF treatment related neurologic symptoms including paresthesias, and potentially other types of adverse effects were usually transient but warrant additional investigation.

AB - Objective: Nerve growth factor (NGF) is a key regulator of nociceptive pain and thus appears to be an interesting target molecule for an innovative class of analgesic medication. We set out to review the principles of neurogenic inflammation and results of anti-NGF regimens in animal studies as well as clinical trials with patients with back pain and osteoarthritis (OA). Design: We searched using Google Scholar Search and Pubmed as well as through conference reports for articles and abstracts related to NGF and clinical trials using anti-NGF regimens. We report on efficacy findings and adverse events (AEs) related to these agents in this review. Results: We identified five full articles and eight abstract reports relating to anti-NGF agents studied for use in back pain and in OA. Conclusions: Anti-NGF agents either alone or in combination with non-steroidal anti-inflammatory agents (NSAIDs) were more efficacious for the treatment of pain in a number of trials of knee and hip pain compared to NSAIDs alone. However, adverse effects that included rapidly progressive OA and joint replacement were more common in patients treated with anti-NGF and NSAIDs than either treatment alone. Anti-NGF treatment related neurologic symptoms including paresthesias, and potentially other types of adverse effects were usually transient but warrant additional investigation.

KW - Nerve growth factor

KW - Neurogenic inflammation

KW - Osteoarthitis

KW - Receptor antagonists

UR - http://www.scopus.com/inward/record.url?scp=84882667218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882667218&partnerID=8YFLogxK

U2 - 10.1016/j.joca.2013.06.004

DO - 10.1016/j.joca.2013.06.004

M3 - Article

VL - 21

SP - 1223

EP - 1228

JO - Osteoarthritis and Cartilage

JF - Osteoarthritis and Cartilage

SN - 1063-4584

IS - 9

ER -